| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Feb 2025 | 6 Feb 2025 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the un-audited Limited Reviewed Financial Results for the Quarter III of Financial Year 2024-25 ended on December 31 2024. Outcome of Board meeting held for ,inter alia, consideration and approval of Unaudited Limited Reviewed Financial Results (Standalone and Consolidated) for the Quarter ended December 31, 2024. (As Per BSE Announcement Dated on: 12/02/2025) | ||
| Board Meeting | 11 Nov 2024 | 5 Nov 2024 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve the Unaudited Limited Reviewed Financial Results (Standalone and Consolidated) of the Company for quarter II and half year ended on September 30 2024 of Financial Year 2024-25. Outcome of Board Meeting held on November 11, 2024 (As Per BSE Announcement Dated on: 11/11/2024) | ||
| Board Meeting | 12 Aug 2024 | 6 Aug 2024 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for the Quarter-1 of financial year 2024-25 ended on June 30 2024 Financial Results for the quarter ended June 2024 (As per BSE Announcement dated on 12/08/2024) | ||
| Board Meeting | 19 Jul 2024 | 17 Jul 2024 |
| Outcome of Board Meeting w.r.t the Re-appointment of Directors and other matters as disclosed in the letter. Considered and approved the Board Report and annexures thereto for the F.Y.2023-24 and Notice of the AGM to be held on August 21, 2024. (As Per BSE Announcement dated on 19.07.2024) | ||
| Board Meeting | 23 May 2024 | 16 May 2024 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 inter alia to consider and approve Audited Standalone & Consolidated Financial Results of the Company for the quarter and financial year ended on March 31 2024. Statement on Nil Deviation or Variation for proceeds of Qualified Institutions Placement for Quarter ended March 31, 2024 Audited Financial Results along with Auditors Report for Financial Year ended on March 31, 2024 outcome of the Board Meeting held on May 23, 2024 (As Per BSE Announcement dated on 23.05.2024) | ||
The inspection raised, seven minor observations none related to data integrity, and therefore, the facility remains compliant under stringent regulatory standards.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
